They are really interested. More and more.
– Will Regenerative Medicine (RegenMed) develop into a separate branch of the biomed industry or will BigPharma and Biotech acquire it?
– What is the way for Regen to collaborate with BigPharma?
– How to raise money from embryonic stem cell technologies?
– Will venture capitalists finally come to the field of RegenMed?
The company created a good model of “stem cell business” and successfully raised a money at the beginning stage.
The company successfully collaborated with BigPharma (Phizer, Merck, Sanofi Aventis) and gives us an example of how it should be done.
To me it is obvious that the future way to go is collaboration between RegenMed (included Stem Cell based companies), BigPharma and Biotech. And I’d agree with Peter Mountford that Genentech gave us the best example how collaboration between BigPharma and Biotech could be done.
Also I think, the Stem Cell Sciences model is the only viable model of making money on embryonic stem cells in next 3 years. Providing cells for Pharma for drug screening and toxicology tests is the way to go.
One more indication for that is this news released last week – 3 UW (University of Wisconsin) spinoffs form major stem cell company (Forbes).
Under a deal announced Monday, Cellular Dynamics International is joining forces with Stem Cell Products Inc. and iPS Cells Inc. Backed by $18 million in private venture capital…
Tests for drug side effects are generally done on animal cells, but that’s less efficient and successful at predicting problems. CDI is already using stem cell technology to supply heart cells to Roche and other drugmakers.